Clinical Trials
64 trialsNatural History Study of Patients With Neurofibromatosis Type 2
National Institutes of Health Clinical Center (CC)
LWBC
University of Colorado, Denver
LUPARPED
Fundación de investigación HM
PRiME II
Washington University School of Medicine
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
Children's Oncology Group
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Rare CNS Tumors Outcomes &Risk
National Institutes of Health Clinical Center (CC)
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
PED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
VBS-CSI-PT-PED
Ruijin Hospital
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
INTUITT-NF2
Massachusetts General Hospital
EViDENCE-BT
University of Zurich
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Regeneron Pharmaceuticals
Methionine PET/CT Studies In Patients With Cancer
St. Jude Children's Research Hospital
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
Pediatric Brain Tumor Consortium
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
PNOC027
University of California, San Francisco
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Seattle Children's Hospital
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
CLOVER-2
Cellectar Biosciences, Inc.
PNOC023
University of California, San Francisco
IMPACT
Children's National Research Institute
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
rQNestin
Dana-Farber Cancer Institute
AflacST1502
Emory University
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
MEMMAT
Medical University of Vienna
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Shengjing Hospital
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Augusta University
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Augusta University
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
The University of Texas Health Science Center, Houston
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Peds CHAMP1ON
University of Florida